An anti-arrhythmic pharmaceutical composition. The pharmaceutical composition includes: an active ingredient, including 1-(3-methanesulfonamido benzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline or a pharmaceutically acceptable salt thereof; and auxiliary materials, including lactose, microcrystalline cellulose and a pre-gelatinized starch, which account for 30% to 80% of the total weight of the composition. The composition has a good dissolution effect and excellent stability, and can be better applied to clinic.

An anti-arrhythmic pharmaceutical composition. The pharmaceutical composition includes: an active ingredient, including 1-(3-methanesulfonamido benzyl)-6-methoxy, 7-benzyloxy-1,2,3,4-tetrahydroisoquinoline or a pharmaceutically acceptable salt thereof; and auxiliary materials, including lactose, microcrystalline cellulose and a pre-gelatinized starch, which account for 30% to 80% of the total weight of the composition. The composition has a good dissolution effect and excellent stability, and can be better applied to clinic.

The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy.

This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

Monocyte-specific nucleic acid aptamers and lipid nanoparticles comprising such for use in drug delivery. Also disclosed herein are use of the aptamer-based lipid nanoparticle drug delivery system for treating heart injury.

The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.

The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.